Cytochrome P450 2D6 polymorphisms and predicted opioid metabolism in african american children with sickle cell disease

Journal of Pediatric Hematology/Oncology

Volumn 35, Issue 7, 2013, Pages

  Yee, Marianne M ^a,b   Josephson, Cassandra ^a,b,c   Hill, Charles E ^c   Harrington, Rosiland ^d   Castillejo, Marta Inés ^c   Ramjit, Ruan ^c   Osunkwo, Ifeyinwa ^a,b  

^a AFLAC   (United States)

^b Departments of Pediatrics   (United States)

^c EMORY UNIVERSITY   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

pain medicine; pharmacogenetics; sickle cell disease

Indexed keywords

CODEINE; CYTOCHROME P450 2D6; HEMOGLOBIN; HYDROCODONE;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ALLELE; ANALGESIA; ARTICLE; CHILD; CYP2D6 GENE; DNA POLYMORPHISM; DRUG METABOLISM; GENE; GENE DELETION; GENE FREQUENCY; GENE FUNCTION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PAIN; PHARMACOGENETICS; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SICKLE CELL ANEMIA;

ADOLESCENT; AFRICAN AMERICANS; ALLELES; ANALGESICS, OPIOID; ANEMIA, SICKLE CELL; CHILD; CYTOCHROME P-450 CYP2D6; GENE FREQUENCY; GENOTYPE; HUMANS; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 84885176621     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31828e52d2     Document Type: Article

References (22)

1. Leppert W. CYP2D6 in the metabolism of opioids for mild to moderate pain. Pharmacology. 2011;87:274-285.
2. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype. Clin Pharmacol Ther. 2012;91: 321-326.
3. Lotsch J, Skarke C, Liefhold J, et al. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet. 2004;43:983-1013.
4. Darbari DS, Minniti CP, Rana S, et al. Pharmacogenetics of morphine: potential implications in sickle cell disease. Am J Hematol. 2008;83:233-236.
5. Daly AK, Brockmoller J, Broly F, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics. 1996;6:193-201.
6. Neafsey P, Ginsberg G, Hattis D, et al. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): population distribution of CYP2D6 activity. J Toxicol Environ Health B Crit Rev. 2009;12:334-361.
7. Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007;7:257-265.
8. Gaedigk A, Ndjountche L, Divakaran K, et al. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin Pharmacol Ther. 2007;81: 242-251.
9. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004;351:2827-2831.
10. Brousseau DC, McCarver DG, Drendel AL, et al. The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis. J Pediatr. 2007;150:623-626.
11. Joly P, Gagnieu MC, Bardel C, et al. Genotypic screening of the main opiate-related polymorphisms in a cohort of 139 sickle cell disease patients. Am J Hematol. 2012;87:534-536.
12. Raimundo S, Toscano C, Klein K, et al. A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther. 2004;76:128-138.
13. Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60:284-295.
14. Cai WM, Nikoloff DM, Pan RM, et al. CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing. Pharmacogenomics J. 2006;6:343-350.
15. Leathart JB, London SJ, Steward A, et al. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics. 1998;8:529-541.
16. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005; 5:6-13.
17. Wijnen PA, Op den Buijsch RA, Drent M, et al. Review article: the prevalence and clinical relevance of cytochrome P450 polymorphisms. Aliment Pharmacol Ther. 2007;26(suppl 2): 211-219.
18. Darbari DS, Neely M, van den Anker J, et al. Increased clearance of morphine in sickle cell disease: implications for pain management. J Pain. 2011;12:531-538.
19. Darbari DS, van Schaik RH, Capparelli EV, et al. UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am J Hematol. 2008;83:200-202.
20. Gaedigk A, Bradford LD, Marcucci KA, et al. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther. 2002;72:76-89.
21. Gaedigk A, Bhathena A, Ndjountche L, et al. Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenomics J. 2005;5:173-182.
22. Wan YJ, Poland RE, Han G, et al. Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California. Pharmacogenetics. 2001;11:489-499.